Exclusive Enteral Nutrition Initiates Individual Protective Microbiome Changes to Induce Remission in Pediatric Crohn's Disease

Häcker, Deborah[1,2]; Siebert, Kolja[3]; Smith, Byron J[4+]; Köhler, Nikolai[5]; Riva, Alessandra[1]; Mahapatra, Aritra[6]; Heimes, Helena[1]; Nie, Jiatong[1]; Metwaly, Amira[1]; Hölz, Hannes[3]; Manz, Quirin[7]; De Zen, Federica[3]; Heetmeyer, Jeannine[3]; Socas, Katharina[3]; Le Thi, Giang[3]; Meng, Chen[8]; Kleigrewe, Karin[8]; Pauling, Josch K[5]; Neuhaus, Klaus[6]; List, Markus[7,9]; Pollard, Katherine S[4,10,11]; Schwerd, Tobias[3&+]; Haller, Dirk[1,2,6&+]

[&]Authors contributed equally, [+]Corresponding author

[1] Chair of Nutrition and Immunology, TUM School of Life Sciences, Technische Universität München, Freising, Germany

[2] TUMCREATE, 1 CREATE Way, #10-02 CREATE Tower, Singapore 138602

[3] Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany.

[4] Gladstone Institutes, San Francisco, CA, USA

[5] LipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, Freising, Germany

[6] ZIEL Institute for Food & Health, Technische Universität München, Freising, Germany

[7] Data Science in Systems Biology, School of Life Sciences, Technische Universität München, Freising, Germany

[8] Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), TUM School of Life Sciences, Technische Universität München, Freising, Germany

[9] Munich Data Science Institute (MDSI), Technical University of Munich, Garching, Germany

[10] University of California, San Francisco, CA, USA

[11] Chan Zuckerberg Biohub

Correspondence:
Prof. Dr. Dirk Haller
Technical University of Munich
Chair of Nutrition and Immunology
Gregor-Mendel-Str. 2
85354 Freising, Germany
Email: dirk.haller@tum.de
Phone: + 49 8161-71 2026

Keywords: pediatric Crohn's disease, Exclusive enteral nutrition - EEN, fiber, medium chain fatty acids, *ex vivo* gut chemostat model, FMT, multi-omics data integration, microbiome, metagenomics, bacterial strain dynamics

Exclusive Enteral Nutrition

Individual profiles in patients

Pediatric Crohn's disease

EEN therapy

MCFAs

EEN-like medium

EEN-like diet

Functional validation

Individual response to therapy

Metagenomic strain profiling
Untargeted metabolite profiling

Summary

Exclusive enteral nutrition (EEN) is the first-line therapy for pediatric Crohn's disease (CD), but protective mechanisms remain unknown. We established a prospective pediatric cohort to characterize the function of fecal microbiota and metabolite changes of treatment-naïve CD patients in response to EEN. Integrated multi-omics analysis identified network clusters from individually variable microbiome profiles, with *Lachnospiraceae* and medium chain fatty acids as protective features. Bioorthogonal non-canonical amino acid tagging selectively identified bacterial species in response to medium chain fatty acids. Metagenomic analysis identified high strain-level dynamics in response to EEN. Functional changes of diet-exposed fecal microbiota were further validated in a combined approach using gut chemostat cultures and microbiota transfer into germ-free *Il10*-deficient mice. Dietary model conditions induced individual patient-specific strain signatures to prevent or cause IBD-like inflammation in gnotobiotic mice. Hence, we provide evidence that EEN therapy operates through explicit functional changes of temporally and individually variable microbiome profiles.

Introduction

Crohn's disease (CD), one of the main entities of inflammatory bowel diseases (IBD), is a chronic and relapsing inflammatory condition of the gastrointestinal tract[1]. Epidemiological studies have demonstrated a significant increase in the incidence of CD in Westernized countries, particularly among the pediatric age group[2,3]. The pathogenesis of IBD involves host genetics and environmental influences, among which diet and the intestinal microbiome are key etiologic factors[4,5].

Exclusive enteral nutrition (EEN) is the first-line treatment for pediatric CD[6,7] and also shows efficacy in adult patients[8]. EEN refers to polymeric liquid formulas, which are mostly devoid of fibers[9]. Re-introducing regular diet after 6-8 weeks of EEN often results in recurrence of inflammation and disease activity[10]. EEN has been shown to drive changes in gut microbiota composition[11], but the high relapse rate after cessation of EEN suggests the presence of a CD-conditioned microbiome, which is able to re-establish after dietary intervention[12]. CD is associated with reduced bacterial diversity, compositional and functional changes, and the disruption of metabolic circuits between microbiome and host[13–15]. Despite recent findings that EEN mediates protective functions in experimental models of colitis[16], human studies revealed incomplete recovery of the intestinal microbiome after antibiotic interventions[17]. Thus, functional evidence for EEN-mediated changes in the human microbiome as an underlying cause of therapeutic efficacy is still lacking.

Here, we identify EEN-protective signatures using integrated microbiota and metabolite
analysis of treatment-naïve pediatric CD patients. Medium chain fatty acids (MCFAs) directly
target bacteria from of the EEN-protective signatures, providing a direct mechanistic link
between diet and microbiota changes. Further, we established a combined gut chemostat-to-
mouse transfer approach to functionally validate EEN-mediated protective changes in the
microbiome of CD patients. We demonstrate that EEN directly shapes microbiomes to mediate
protective functions in treatment-naïve CD patients, operating through explicit patient-to-
patient changes of temporally and individually variable strain profiles.

Results

Microbiota and metabolite profiling identify individual responses to EEN therapy in
pediatric CD patients

We established a pediatric IBD cohort and longitudinally followed 78 IBD patients, showing no
disease specific but individual bacterial and metabolite profiles in fecal samples (**Fig. 1A, S1A-**
C). To gain insides in mechanisms of EEN therapy, we focused explicitly on 20 newly
diagnosed and treatment-naïve CD patients, receiving EEN as induction therapy (CD-EEN
group, 9 females, age at study inclusion 12.5 ± 3.1 years) (**Fig. 1A, S1A; Table S1**). EEN was
highly effective and significantly improved disease activity and inflammatory markers at the
end of EEN treatment, resulting in clinical response and induction of remission in 20/20 and
18/20 patients, respectively (**Fig. 1B**). During follow-up, patients received methotrexate (6/20),
anti-TNF (13/20), or combination therapies (9/13) as maintenance treatment. Relapse after
EEN was observed in 8/20 patients over one-year follow-up (**Fig. 1B**). Two patients switched
from Modulen IBD® to Neocate Junior® during EEN due to suspected cow's milk protein
allergy.
95
Analysis of samples before (PreEEN), during (EEN), and after EEN therapy (PostEEN)
(microbiota profiling: 291 samples, metabolomic analysis: 145 samples) revealed patient-
specific responses (**Fig. 1C, D**). Bacterial richness based on zOTUs (zero-radius operational
taxonomic units) changed individually during formula feeding (**Fig. S1D**) but was lower during
active CD compared to remission (**Fig. S1E**). Samples of EEN-treated patients are scattered
throughout dendrograms of microbiota and metabolome profiles (**Fig. 1C, D**). Despite
considerable overlap in multi-dimensional scaling (MDS) plots based on microbial profiles,
linear mixed models (LMMs) identified only diet as significantly contributing to the first MDS
dimension (x-axis) (**Fig. 1E**, n=277, p-value < 0.0001; **Fig. S1F**). PCA plots of metabolic
profiles also showed significant separation according to diet along PC2 but no separation
according to disease activity (**Fig. 1F**, n = 141, p-value < 0.0001; **Fig. S1G**).

Integration of microbiota and metabolome data identifies key features of EEN exposure

To identify key differences between fecal microbiota and metabolite profiles of patients collected under EEN (therapy, partially with still active disease) and PostEEN conditions (receiving regular diets but completely in remission), a network analysis incorporating matched zOTU taxonomic profiles and untargeted metabolomics from 60 samples was performed. The identified interlinked features clustered in five distinct network communities (**Fig. S2**). In summary for the top selected features from the correlation network, higher mean importance was found for zOTUs associated to EEN compared to zOTUs associated with PostEEN (**Fig. 1I**). The top eleven zOTUs associated to EEN were found within all communities (**Fig. 1I**, green gradient), including several zOTUs from the genera *Enterocloster* and *Clostridium* (formerly *Lachnoclostridium; Lachnospiraceae;* **Table S2**) which still showed individual abundances in each patient (**Fig. S3A**). Of the 22 top selected metabolite features, the majority were associated with PostEEN, whereas six metabolites were associated with EEN with higher mean importance (**Fig. 1J**). Of the in total ten metabolites associated with EEN, the majority of those were medium chain fatty acids (MCFA) (palmitoleic acid, decanoic acid, caprylic acid and lauric acid) which were identified as metabolite features present in Modulen IBD® (**Fig. S2C, S3B**).

Medium chain fatty acids selectively induce translational activation of fecal bacteria

Three MCFAs [(lauric acid (LA), decanoic (DA) acid and octanoic acid (OA)] were identified as signature metabolites of EEN, likely originating from IBD Modulen. To determine which gut bacteria can be activated by these metabolites, we employed a combination of bioorthogonal noncanonical amino acid tagging (BONCAT) and fluorescence-activated cell sorting (FACS) to identify translationally active bacteria in the presence of MCFAs under *ex vivo* anaerobic incubations (**Fig. 2A**). We selected three donors (MP1-MP3, model patient) within the CD-EEN group based on clinical activity, limited drug exposure and chose four different samples along EEN therapy (**Table S3,** STAR Methods, **Fig. 4A, C, I; S8F**). Confocal microscopy visualization and quantification indicated that a significantly higher proportion of gut bacteria became translationally active after exposure to MCFAs, compared to the solvent control (**Fig. 2B, C; Fig. S4, S5**). The MCFA-active fraction of the community (BONCAT labeling and FACS sorting), exhibited significant differences compared to the unsorted community and between patients as shown in the MDS ordination (p = 0.001, **Fig. 2D**). Ethanol mediated variability is shown as additional control (**Fig. S5C**). This separation highlights distinct microbial communities to be present after MCFAs exposure. We identified different zOTUs enriched in the active fraction after exposure to MCFAs compared to the ethanol control (**Fig. 2E, S5; Table S4, S5**). Different species from the *Enterocloster* genera were significantly enriched in

response to MCFAs, especially in MP2 at EEN remission stage (**Fig. 2E**). This includes

Enterocloster aldensis and two subspecies of *Enterocloster boltae*, which aligns with the

bacterial signature identified from the clinical cohort (**Fig. 1G**). Additional enriched taxa

included *Eggerthella lenta* in MP2 (remission); *Escherichia coli, Clostridium scindens, Dialister*

invisus, Sporobacter spp. *and Eubacterium* spp. (MP2 relapse); *E. coli* in MP1 and MP3 as

well as *Lachnospiraceae* in MP1. In contrast, several additional zOTUs were depleted in the

active fraction after MCFA exposure including *Clostridium scindens, Thomasclavelia ramosa,*

Hungatella hominis, Peptostreptococcus anaerobius, Ruthenibacterium lactatiformans and

Phocaeicola vulgatus in MP2 at EEN remission stage and *Anaerostipes hadrus* and

Hominenteromicrobium mulieris in MP2 under relapse (**Fig. 2E, S5, Table S4, S5**). In

summary, of the 16 zOTUs associated with EEN from the Network analyses, 8 zOTUs

responded to MCFA exposure (labeled with * in **Fig. 1G, S2C**).

Microbial species, strains, and functions change dramatically at EEN cessation

Considering the various changes of community profiles associated with EEN or PostEEN, we

next investigated dynamics within the patients along EEN therapy. Cessation of EEN resulted

in an elevated turnover in zOTU composition (**Fig. 3A**), resulting in higher dissimilarity - even

after controlling for greater time periods - between pairs of samples spanning the transition off

of EEN compared to during or post-EEN alone ($p < 10^{-3}$ for both comparisons by permutation

test). Using shotgun metagenomes for 96 CD-EEN patient samples (n = 19 patients), we

applied StrainFacts[18] to resolve taxonomic differences below the level of species. Like zOTUs,

and despite the much smaller number of comparisons, we detected the same elevated turnover

in the composition of strains during the transition off of EEN relative to the PostEEN period (p

$< 10^{-3}$, **Fig. 3B**). Overall, we observed high strain-level diversity within and between CD-EEN

patients. For most of the 369 species, individual strains were largely specific to a single patient

and appeared in multiple samples from their host, while some samples contained multiple

distinct strains of a given species (e.g. **Fig. 3D-F**).

Besides taxonomic turnover, we also detected 583 protein coding gene families (COGs) with

substantial changes in their normalized abundance (54 increased and 529 decreased) at the

transition off of EEN (**Fig. 3C**). Families increased during EEN included COG3845 (mean log2

PostEEN/EEN of -0.58) and COG4603 (-0.58), components of the ABC-type guanosine uptake

system. Increases in COG4813 (+2.1), annotated as trehalose utilization protein, and

COG3867 (+1.0), arabinogalactan endo-1,4-beta-galactosidase, indicate that microbes

encoding these proteins respond to host diet and may play a role in metabolite transformations.

These findings are consistent with changes in carbohydrates and sugar acids found in the

metabolite analysis (**Fig. S2C**).

Next, we sought to identify species with high prevalence and abundance and with large

changes in relative abundance or extensive strain turnover at the end of EEN. Using an

indicator score based on these features (**Fig. S2A, Table S7**), we flagged 46 species as highly

dynamic. We identified pairs of zOTUs and metagenomic species (**Table S6**) and matched 37

(80%) of the top scoring species (**Fig. S6B, Table S7**). Here we highlight and contrast the

strain dynamics of two closely related species, *Enterocloster bolteae* (formerly

Lachnoclostridium bolteae) and *E. clostridioformis* (formerly *C. clostridioforme*). Both of these

species were matched to zOTU5 (**Fig. S6C**) and showed dynamic strain composition over

patient time series (**Fig. 3D, E**). In some patients, EEN and PostEEN samples contained similar

strains of each species, but the dominant strain changed; in others, a new strain appeared

PostEEN that was absent or undetectable during EEN. Interestingly, the relative abundance of

E. bolteae, but not *E. clostridioformis*, was significantly affected by EEN cessation (p = 0.018

and 0.9, respectively, by Wilcoxin test; **Table S7**). Hower, while both showed a similar strain

turnover overall, *E. clostridioformis*, but not *E. bolteae* had significantly elevated strain turnover

at the transition from EEN to PostEEN (p = 0.004 and 0.202, respective, by permutation test:

n=999). This effect was also seen in nine other common species (**Table S7**), including *E. coli*

(**Fig. 3F**). By contrast, some species like *Bacteroides uniformis* revealed notably lower strain

diversity within samples and across time (**Fig. S6D**).

The distinction in response to EEN among strains and between closely related species

reinforces the importance of strain-level characterization in individuals. Altogether,

metagenomic analyses demonstrate that gut microbial communities are dynamic at and below

the species level and highly influenced by EEN, motivating us to explore their relationship to

the clinical efficacy of EEN.

EEN-like diet triggers protective changes in fecal microbiota

To further evaluate the functional impact of EEN on patient-derived fecal microbiota, we used

continuous culture systems in a gut chemostat model and fecal microbiota transfer (FMT) into

germ-free (GF) WT and *Il10*$^{-/-}$ mice. *Il10*$^{-/-}$ mice are a microbiota-dependent IBD mouse model

responsive to human fecal microbiota, as previously shown for adult CD patients[19] (**Fig. 4A**).

The previously used samples from model patients (MP) for the BONCAT experiments were

also selected for the transfer experiment (**Fig. 4B, C, I**; **Table S3**, STARMethods).

Microbiota transfer of the PreEEN sample of MP1 (MP1-FMT 1, **Fig. 4B,** red arrow) induced

colonic tissue inflammation in all gnotobiotic *Il10*$^{-/-}$ mice (histopathology score of 5.3 ± 1.0) but

not in WT control mice (**Fig. 4D** p < 0.001, histopathology score of 1.3 ± 0.5; **Fig. S7A** H&E),

mirroring the active disease state of this patient. Following transfer of MP1 fecal material into

the gut chemostat model (MP1-FMT 2, **Fig 4A**), dietary exposure was mimicked using

combinations of fiber-free EEN-like (including 10% Modulen IBD® of the 1 kcal/mL

preparation) and fiber-repleted (FR) medium, respectively (**Fig. S8A, B**). We then transferred

microbiota (MP1-FMT 3) from the chemostat model exposed to EEN-like medium and thereby

reversed the inflammatory phenotype of MP1 in $Il10^{-/-}$ mice (**Fig. 4D**, histopathology score of

$Il10^{-/-}$ mice = 2.5 ± 0.8; WT mice = 1.6 ± 0.5; FMT1 vs FMT 3 $Il10^{-/-}$ p <0.001; **Fig. 4F** H&E, **Fig.**

S7A). Conversely, under fiber-repleted medium conditions MP1-FMT 4 induced IBD-like tissue

pathology in four out of six $Il10^{-/-}$ mice (**Fig. 4D** histopathology score = 3.7 ± 1.0; **Fig. 4F** H&E,

Fig. S7A), compared to disease-free WT mice (**Fig. 4D** histopathology score = 1.4 ± 0.5, p =

0.0087; **Fig. 4F** H&E, **Fig. S7A**). *Tnf* gene expression confirmed active tissue inflammation

with significantly elevated expression levels in $Il10^{-/-}$ compared to WT mice (**Fig. 4F** p = 0.0022

dist. (distal) colon; **Fig. S7D** p = 0.0152 prox. (proximal) colon). Thus, *ex vivo* EEN-like

intervention recapitulated therapeutic functional changes to the microbiota.

Transfer of the fecal microbiota from MP2 failed to induce inflammation in $Il10^{-/-}$ mice (MP2-

FMT 1, **Fig 4E** H&E, **Fig. S7B**), resembling the inactive disease state of the patient. Since the

stool sample of MP2 was retrieved under EEN therapy, we started the gut chemostat on EEN-

like medium (MP2-FMT 2; **Fig. S8C**). In contrast to MP2-FMT 3 (**Fig. 4E** histopathology score

in in $Il10^{-/-}$ = 2.0 ± 0.6; WT = 1.0 ± 0.6; **Fig. 4G** H&E**, Fig. S7B**), transfer of FR-conditioned

microbiota (MP2-FMT 4) triggered IBD-like colitis, including histopathologic changes and

elevated *Tnf* tissue expression (**Fig. 4E**, histopathology score in $Il10^{-/-}$ = 4.8 ± 1.9 *vs*. WT = 1.5

± 0.5, p ($Il10^{-/-}$ FMT1 *vs*. FMT4) = 0.0004, p ($Il10^{-/-}$ FMT3 *vs*. FMT4) = 0.0008 ; **Fig. 4G** H&E,

Tnf gene expression p = 0.0152 dist. colon; **Fig. S7D** p = 0.0022 prox. colon). Thus, both

transfer experiments (MP2-FMT 1 and MP2-FMT 3) demonstrate protective effects of EEN.

Reintroduction of fiber (MP2-FMT 4) reverted this protective function, indicative for the risk of

relapse in MP2 after EEN cessation (**Fig. 4C**).

Next, we introduced an EEN-like mouse diet one week prior to FMT (MP3-FMT 4) to evaluate

extended dietary effects in gnotobiotic WT and $Il10^{-/-}$ mice (**Fig. 4H**). MP3 had elevated fecal

calprotectin levels of 2828 mg/L (**Fig. 4I**, blue arrow) and ongoing mucosal inflammation with

endoscopic signs of disease activity (**Fig. 4I**, grey arrow), despite achieving clinical remission

under EEN therapy. Accordingly, FMT 1 from MP3 induced severe inflammation in all recipient

$Il10^{-/-}$ mice (**Fig. 4J** histopathology score in $Il10^{-/-}$ = 7.3 ± 0.8 *vs*. WT = 1.3 ± 0.5, p = 0.0022;

Fig. S7C H&E). In contrast to MP1 and MP2 (**Fig. 4D, E**), EEN-like medium in the chemostat

model did not change the inflammatory phenotype in IBD-susceptible mice (MP3-FMT 3, **Fig.**

4J histopathology score in $Il10^{-/-}$ = 6.0 ± 1.3 *vs*. WT = 1.6 ± 1.0, p = 0.0006; **Fig. 4K** H&E, **Fig.**

S7C; *Tnf* p = 0.0022 for dist. colon and prox. colon; **Fig. S7D**). However, introducing EEN-like

diet decreased the level of disease severity after MP3-FMT 4 in most $Il10^{-/-}$ mice (**Fig. 4J**

histopathology score in EEN-like-fed $Il10^{-/-}$ = 3.2 ± 3.1 *vs*. WT = 1.3 ± 0.5, p = n.s.; **Fig. 4K**

H&E, *Tnf* p = n.s dist. colon; **Fig. S7C, D,** *Tnf* p = 0.0022 for prox. colon) and significantly

reduced disease activity compared to the chow-fed group (**Fig. 3J** FMT 3 *vs.* FMT 4,

histopathology score in EEN-like-fed *Il10*$^{-/-}$ = 3.2 ± 3.1, p = 0.0271, *Il10*$^{-/-}$ FMT 1 *vs.* FMT 4 p =

0.0005**, Fig. 4K** H&E, **Fig. S7C**). An additional sample of MP2 after clinical relapse was tested

under conditions of the extended EEN-like feeding (**Fig. S8F**, orange arrow), and contrary to

MP3, the MP2 relapse sample was resistant to EEN induced protection (**Fig. S8E-L**). These

findings suggest that sustained EEN-like feeding increased the chance to prevent recurrence,

but efficacy of repeated EEN decreases with a second course.

Individual strain signatures in gnotobiotic *Il10*$^{-/-}$ mice convey protective function of

patient's microbiota in response to diet

To investigate bacterial strain profiles responsible for the mouse disease phenotypes (**Fig. 4**),

we performed metagenomic analyses of all 54 gnotobiotic *Il10*$^{-/-}$ mice colonized with fecal

communities of MP1-MP3 (**Fig. 5A-C,** triangles: red - active disease, green - inactive disease;

Fig. S9A). Out of 100 strains detected in MP1, 64 were specific to mice with active disease,

while only three were specific to inactive disease (**Fig. 5A,** lowest Venn diagram (Vd)). Strains

in MP2 mice were skewed towards being specific to inactive disease or shared (**Fig. 5B,** lowest

Vd), consistent with lower disease activity in MP2 and fewer mice with active disease. Strains

in MP3 mice were skewed towards being specific to active disease, probably due to a higher

number of MP3 mice having active disease (**Fig. 5C,** lowest Vd).

Motivated by these differences, we next sought to identify species, strains, and metabolites

that distinguished active *vs.* inactive *Il10*$^{-/-}$ mice. Dozens of species showed significant

differential abundance after the transfer experiments of MP1, MP2 and MP3 (40, 16 and 11,

respectively **Fig. 5D-F**) including taxa from the network analyses and BONCAT experiments.

Considering all microbiota transfer experiments, we detected 181 species, including 24

species shared between MP1-MP3 transfer experiments into *Il10*$^{-/-}$ mice (**Fig. 5G, left** Vd). In

contrast, none of the identified species shared any common strain within all (**Fig. 5G,** right Vd),

demonstrating that active *vs.* inactive disease states in *Il10*$^{-/-}$ mice are mediated by individually

variable strain communities. Linear discriminant analysis Effect Size (LEfSe) determined 47

species that were differentially abundant between mice with active *vs.* inactive disease, each

with individual strain repertoires in samples from the three different MPs (**Fig. S10A**). In the

combined analyses *E. clostridioformis* (zOUT5) and *Bacteroides thetaiotaomicron* (zOUT2,

zOTU66) were most dominant in mice with active disease and *Akkermansia muciniphila*

(zOUT65) and *Escherichia coli* (zOTU4, zOUT8) were most dominant in mice with active

disease (**Fig. S10A**). In addition, 56 species were significantly different in abundance

comparing mice under chow vs EEN-like diet (**Fig. S10B**) with previously highlighted strains

abundant in both groups, as mice colonized with *ex vivo* EEN-conditioned microbiota received

either chow or EEN-like diet. Importance of strain level diversity, is obvious as several species

were associated to both, active and inactive mice, in the different MP transfers, but the different

strains were responding differently in the model systems (**Fig. 5D-G, S10A**).

SPLS-DA of untargeted metabolomics from mouse colon content separated active and inactive

mice in the respective transfer experiments independent of dietary exposure (**Fig. S9B-D,**

S10C-F). Several bile acids (BA) were highlighted as differentially abundant, which was

confirmed in the targeted measurement primary taurine conjugated and secondary

unconjugated BA (**Fig. S9B, C**). Targeted analyses of Isobutyrate showed highest

concentration in mouse feces samples colonized with EEN conditioned microbiota on EEN-

like diet (**Fig. S9E**). SPLS-DA of the combined untargeted metabolomics dataset confirmed

distinct clusters for active and inactive disease independent of MP1-3 donor samples (**Fig.**

S10F, **Fig. S11**), suggesting that individual strain profiles convey protective or aggressive

responses in the IBD susceptible host (**Fig. S12**). These results clearly demonstrate that

despite the model patients having personalized strain composition (**Fig. 5G,** right Vd), disease

activity in gnotobiotic mice receiving FMTs was consistently associated with a number of

metabolic and species-level taxonomic differences. Furthermore, the differentially abundant

species in all humanized mice exhibited unique patterns linked to EEN and its cessation in the

CD patient cohort (**Fig. S13**), emphasizing both the clinical relevance of our mouse FMT

experiment findings and the individual microbial fingerprint of each patient.

In summary, we provide evidence that EEN impacts the individual gut microbiome – EEN

therapy in the CD-EEN patients, selected fecal samples from three individuals exposed to

MCFAs and EEN-like exposure in a non-host and host environment – leading to individual

microbiota changes that are functionally relevant and harboring the capacity to induce or not

to induce inflammation in mice. Despite the limited selection of donor samples, of the 16 EEN

associated zOUTs from the network analyses, 7 zOTUs were found in significantly different

abundant taxa in the mouse experiments (**Fig. 5D-F**) and 8 zOTUs were identified in the

BONAT experiments (**Fig 2E, S5D**), suggesting a direct link of MCFAs in EEN to changes in

the fecal microbiota of CD patients. The microbiota transfer studies in the gut chemostat model

provides proof-of-concept that microbiota changes are functionally relevant and diet shapes

individual microbiota signatures harboring the capacity to induce or not to induce inflammation

in mice. In conclusion, we provide evidence that EEN therapy creates explicit functional

changes of temporally and individually variable microbiome profiles in CD patients. These data

challenge the concept that protective microbiome signatures are universal to patients and

therapeutic interventions, instead we postulate individually diverse microbiome signatures with

shared functional properties under these therapeutic conditions.

Discussion

We followed 78 pediatric IBD patients longitudinally, focusing on 20 newly diagnosed CD

patients receiving EEN as first-line treatment. Our results corroborate previous observations

that EEN is highly effective at inducing remission. We demonstrate that protective functions of

EEN therapy are mediated through diet-induced changes in patient microbiomes despite

considerable variations in individual microbiota over time. Dietary exposure of EEN

components like MCFAs and EEN-like diets on individual patient-derived fecal microbiota

modified the activity and function of selective taxa. EEN mediated changes of fecal bacteria in

the chemostat models convey anti-inflammatory phenotypes after FMT into IBD-relevant GF

mice, strongly supporting a causal role of EEN-mediated protective changes in the

microbiome. In contrast, fiber-repleted diets antagonized these protective functions. Notably

and based on the model conditions, we identify patient-specific species and strain signatures

in response to EEN therapy, confirming the highly personalized strain-level dynamics in

patients and the absence of universal protective signatures.

Longitudinal sampling revealed an integrated network of taxonomic and metabolomic

signatures across pediatric CD patients. In line with previous findings[20], EEN therapy was

associated with the genus *Enterocloster* (Lachnospiraceae; former genus *Lachnoclostridium)*.

In addition, several *Enterocloster* species responded to MCFA exposure, *E. clostridioformis*

(zOUT5) was the most abundant species in inactive *Il10*[-/-] mice and showed high dynamics in

the CD-EEN cohort together with *E. bolteae* (zOTU5). Low levels of *Lachnoclostridium* have

been associated with CD[21], supporting a protective function of *Enterocloster* in response to

EEN therapy. Nevertheless, taxonomic shifts at the cessation of EEN were highly patient-

specific. For example, while in the majority of patients, *E. bolteae* (zOTU5) was at much higher

relative abundance during EEN compared to PostEEN, the dominant strains in many patients

changed over this transition, and most strains were detected in just one subject. This individual

diversity and turnover contribute to challenges in predicting taxonomic responses to dietary

changes globally. Antibiotics and pre-existing dysbiosis are both associated with increased

strain engraftment in patients receiving fecal microbiota transplants[22]. Likewise, the

microbiome perturbation caused by EEN - and its cessation - may encourage strain turnover

in some species, with potentially complex consequences for microbial function after therapy.

Beyond taxonomic alterations, we highlighted six metabolites associated with EEN treatment

and 16 metabolites associated with PostEEN samples. Independently, metagenomic analysis

highlighted 583 bacterial gene functions with substantial changes in response to EEN,

suggesting specific metabolic adaptations of the microbiota to host diets. Modulen IBD® is

characterized by easily digestible carbohydrates and high fat content, including medium-chain

triglycerides[9]. Our integrated network analysis highlighted caprylic (C8:0), decanoic (C10:0),

and lauric (C12:0) acids as associated with EEN. MCFAs are part of the EEN formula and

mediate anti-bacterial and anti-inflammatory functions[23–25]. The exposure of LA, DA and OA to selected patient samples directly link nutritional components of EEN to selectively activated taxa in the microbiota of CD patients. Surprisingly, from the limited selection of donor samples, 50% (8 out of 16 zOTUs) of the EEN associated bacteria significantly responded in the BONCAT experiments. Diets high in fat trigger release of bile acids[26], providing a rationale for *C. innocuum* and *Hungatella hathewayi* to be associated with EEN [27,28]. Concordantly, our untargeted metabolomics analysis identified several bile acids as differentially abundant, highlighting a potential microbial conversion of primary to secondary bile acids in non-inflamed $Il10^{-/-}$ mice, potentially promoting wound healing and epithelial regeneration[26]. In a recent study (FARMM), EEN specifically affected amino acid pathways in the microbiome creating a metabolite milieu low in bacteria-derived indoles[17], which was also low abundant in the EEN-like mouse diet. In addition, EEN-related protective effects in $Il10^{-/-}$ mice are partially mediated by Isobutyrate production[16], which was highest in mice receiving EEN-conditioned microbiota on EEN-like diet, supporting the hypothesis that microbiota and metabolite changes contribute to the EEN therapeutic efficacy.

In healthy humans, dietary fiber intake supports beneficial functions of the gastrointestinal tract[29]. In animal models, low fiber diets induce adverse microbiota changes associated with impaired intestinal barrier integrity and bacteria-related mucus degradation[30,31], highlighting the fiber paradox in understanding EEN-mediated anti-inflammatory mechanisms in IBD. Dietary fiber consists of complex carbohydrates, which are resistant to digestion and absorption by the host. However, dietary fiber degradation and availability for the host depends on the fermenting potential of host-specific microbial communities, which are modified by intestinal inflammation[29,32–34]. Using the combined gut chemostat-to-mouse transfer approach, we showed that a fiber-free EEN-like medium maintains the anti-inflammatory and remitting phenotype associated with EEN therapy. Concordantly, the protective effect of EEN-conditioned microbiota is reversible upon exposure to fiber-repleted diet, as a proxy for regular diet PreEEN and PostEEN, and potentially resistant to repetitive EEN as shown before[12]. A potentially adverse effect of fiber in IBD was elucidated by Armstrong and colleagues, demonstrating the incapability and loss of function of bacteria to degrade fibers promoting intestinal inflammation[34]. Furthermore, several additional studies link the presence of dietary fiber with increased inflammation[35,36]. In addition, fiber-free diets prevent and diminish the colonization of identified pathobionts in different CD-like mouse models[37,38], supporting our hypothesis that EEN therapy directly creates protective niches in the gut microbiome. Preserving a beneficial microbiome after cessation of EEN may be a new approach to guide mucosal healing and remission in pediatric CD[39]. In our IBD cohort, 40% (8/20) of pediatric CD patients relapsed within the first year after EEN treatment, highlighting the necessity to maintain remitting conditions. Our data clearly demonstrate that EEN therapy mediates

394   protective changes in individually variant microbiome profiles, leading towards personalized

395   patient-to-patient species and strain signatures. These findings support the idea to develop

396   patient-tailored maintenance strategies in pediatric CD involving combinations of personalized

397   nutritional and bacterial interventions.

Acknowledgement

We thank the patients and their families for participating in our research.

Author contribution

DHaller and TS are responsible for the conceptual design of the study; DHäcker and DHaller designed the *ex vivo* experiments; KSiebert, HHölz, JHeetmeyer, FDeZen, GLeThi, TS: collected and prepared clinical data and samples, accompanied, followed and characterized patients, analysis of clinical data; HHölz, TS recruited patients; DHäcker, HHeimes, AMetwaly and DHaller performed and interpreted mouse and fermenter experiments; AR and JN performed BONCAT experiments and analyses; DHäcker performed 16S rRNA gene amplicon and corresponding statistical analysis with support of QM and ML; CM, QM, KSocas, ML, KK performed metabolomics with statistical analysis; KSiebert, DHäcker, NK, AMetwaly, ML responsible for integration of clinical metadata with 16S and metabolomics as well as sample selection and performance of data integration and network analysis; NK, ML, PJK performed 16S & untargeted metabolomics data integration, untargeted metabolomics data analyses; BS, AMahapatra, KSP performed metagenomic sequencing and analyses; KN provided 16S rRNA gene amplicon and metagenome sequencing and support for analysis; DHäcker, KSiebert, BS, NK, KSP, TS and DHaller evaluated and interpreted data and wrote the manuscript; All authors provided input on the manuscript, critically revised and approved the final version of the manuscript.

Funding

Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 395357507 (SFB 1371, Microbiome Signatures) and The Leona M. and Harry B. Helmsley Charitable Trust (project numbers 2847 and 2304-05970). TS is supported by the Medical & Clinician Scientist Program (MCSP) of the Faculty of Medicine at LMU Munich. Salary for DHäcker was supported by the National Research Foundation, Prime Minister's Office, Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) programe.

Conflict of interest

DHaller served on the Microbiome Expert Panel from Reckitt Benckiser Health Limited. TS received lecture honoraria from Nutricia and MSD and travel support from Abbvie and Ferring outside the submitted work.

430 ORCID IDs

Deborah Häcker https://orcid.org/0000-0001-7914-9470

Kolja Siebert https://orcid.org/0009-0005-8083-7074

Byron J Smith https://orcid.org/0000-0002-0182-404X

Nikolai Köhler https://orcid.org/0000-0002-5103-883X

Alessandra Riva https://orcid.org/0000-0002-5724-7616

Aritra Mahapatra https://orcid.org/0000-0003-0078-8590

Jiatong Nie https://orcid.org/0009-0007-3192-0095

Amira Metwaly https://orcid.org/0000-0001-5740-0230

Hannes Hoelz https://orcid.org/0000-0002-7208-6195

Quirin Manz https://orcid.org/0000-0002-5706-2718

Jeannine Heetmeyer https://orcid.org/0000-0002-0599-9613

Katharina Socas https://orcid.org/0009-0003-8625-4879

Giang Le Thi https://orcid.org/0000-0002-2504-9551

Chen Meng https://orcid.org/0000-0002-5968-6719

Karin Kleigrewe https://orcid.org/0000-0002-7718-0252

Klaus Neuhaus https://orcid.org/0000-0002-6020-2814

Markus List https://orcid.org/0000-0002-0941-4168

Katherine S Pollard https://orcid.org/0000-0002-9870-6196

Tobias Schwerd https://orcid.org/0000-0002-2281-4852

Dirk Haller http://orcid.org/0000-0002-6977-4085

Figure 1

Figures

Figure 1: Fecal microbial and metabolic changes in response to EEN.

*Patients of the Pediatric IBD cohort with focus on 20 newly diagnosed and treatment naïve CD patients, receiving EEN induction therapy. Longitudinal collected samples (n = samples, N = patients) that were used for 16S rRNA amplicon and metagenomic sequencing as well as metabolome analysis are shown. Paired samples (n = 60) were used for data integration of 16S rRNA and metabolome data (samples highlighted in blue = taken under EEN, orange = taken PostEEN). **B** Weighted pediatric Crohn's Disease activity index (wPCDAI) over time (EEN shaded blue), remission achieved below 12.5 points (dashed line). pE = PreEEN, EE = EEN, PE = PostEEN. **C** Beta-diversity analysis of the fecal microbiota samples. The circular dendrogram shows differences in beta-diversities from the longitudinal microbial profiling based on generalized UniFrac distances between the 291 stool samples of the 20 patients. Indicated in color code are the patients and samples collected during EEN. Color code of taxonomic composition at phylum level as in B. Branch color indicates results of unsupervised clustering. Patient colour code found in B. **D** Visualization of untargeted metabolome samples from 18 newly diagnosed pediatric CD patients receiving EEN therapy: Complete clustering with Euclidean distance of longitudinal samples from 18 CD-EEN patients (n = 145), Patient colour code found in B. **E** Beta-diversity MDS plot samples during EEN (n = 89, active: 55, inactive: 34) vs. PostEEN (n = 188, active: 41, inactive: 147). **F** Analyses of untargeted metabolomics with representative PCA plot comparing samples during EEN (n = 35, active: 21, inactive: 14) and PostEEN (n = 106 active: 21, inactive: 85). Axes indicate principal components (PC), with PC1 representing the most variation (%) and PC2 representing the second most variation (%). (**E, F**) Coefficients were tested with a t-test, reported p-values are Bonferroni-corrected, D = diet, A = activity, D:A = interaction term between diet and activity. **G, H** Heatmaps depicting the abundances of the top selected feature from the correlation network Supplementary Fig. S2. Selected sPLS-DA features were subsetted by their mean importance (see Star Methods: Data integration of 16s rRNA amplicon data with metabolomics and metagenomics for details). All values shown are feature-wise z-scores. Information on association with EEN (blue), PostEEN (orange), sample collection under which diet (EEN blue), PostEEN (orange), community association (1 – 5) are indicated; **G** zOTUs,*BONCAT responders Fig.2, **H** Metabolites.*

Figure 2

Figure 2: MCFAs-Induced Activation of Translationally Active Gut Bacteria.
A Experimental design. MP1, MP2 and MP3 stool samples previously stored in glycerol, were incubated under anaerobic conditions and in the presence of medium chain fatty acids (MCFA)[(lauric acid (LA), decanoic acid (DA) and octanoic acid (OA)] and of the cellular activity marker (L-Azidohomoalanine (AHA). Translationally active bacterial cells labelled with alkyne-modified dye were sorted with BONCAT-FACS. The taxonomic profiles of sorted and unsorted cells were identified by 16S rRNA genes amplicon sequencing. **B** Representative confocal microscopic images of one stool samples (MP2) stimulated with OA. Pink: active cells (BONCAT-Cy5); Blue: all cells (DAPI). Scale bar is 10μm. **C** Translationally active bacterial cells quantified in MP1, MP2 and MP3 patients. P values were calculated by Kruskal-Wallis test and Dunn test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. **D** Beta-diversity MDS plots shows clustering of samples based on model patients and sorted-unsorted groups (perMANOVA p=0.001 for both comparisons). MP1 = orange, MP2 = green, MP3 = turquoise, sorted cells = square, unsorted cells = circle. **E** Relative abundances of significant enriched and depleted zOTUs in MP1, MP2 and MP3. *zOUTs identified in Network analyses Fig 1G, S2. P values were calculated by ANOVA and Tukey's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Figure 3

Figure 3: Species and strain turnover during the transition off of EEN:

A, B *Turnover of taxonomic composition during the transition from EEN to a PostEEN diet of both **(A)** zOTU and **(B)** strain compositions. The three lines reflect cubic spline regression of Bray-Curtis dissimilarities against time, averaged across subjects and offset by an independent intercept for each pair type. **C** Volcano plots showing COGs with significant changes in normalized abundance at the transition off of EEN (Wilcoxon test at false discovery rate (FDR) < 0.1). Here, 54 COGs were at significantly greater relative depth during PostEEN (orange points) and 529 during EEN (blue). **D-F**. Composition over time of strains within **(D)** E. bolteae (red box), **(E)** E. clostridioformis (blue box), **(F)** E. coli (black box) all three abundant in the CD-EEN patients: All three species have notable strain dynamics during and after EEN. Strain genotypes and fractions were estimated from shotgun metagenomic data. Fractions of abundant strains (colored bars) are shown across samples from individual subjects (P01, P02…), before EEN ("pE" labels on x-axis), during ("EE") and after ("PE"). *Samples used as donor samples in other experiments. Strain fractions for the species sum to 1; minor strains are summed together and shown in grey. An analogous plot for B. uniformis is in Supplementary Figure S4D.*

Figure 4

Figure 4: Functional validation of gut microbiota-dependent EEN-efficacy using ex vivo **fermentation and**
gnotobiotic humanized mice.
A *Experimental scheme: FMT 1, Patient sample is transferred into GF mice at the age of 8 weeks for 4 weeks.*
Same patient sample is also transferred (FMT 2) in an ex vivo *gut chemostat model and treated with medium*
simulating EEN (EEN-like, devoid of fibers) or a regular diet (fiber-rich, FR). Fermented sample is transferred (post
ex vivo) into GF mice (age of 8 weeks) for 4 weeks (FMT 3 - EEN-like medium conditioned, FMT 4 - FR medium
conditioned). **B, C** *Transfer of patient sample: patients disease state with wPCDAI and fecal calprotectin levels,*
therapy response over time with maintenance therapy (MTX, Anti-TNF) and sampling time point. **B** *Model Patient*
(MP) 1, sample (red arrow) collected PreEEN in active disease. **C** *MP2, sample (blue arrow) collected in EEN*
induced remission. **D** *Mouse histopathology scoring of colon Swiss roles of FMT 1, 3 and 4 from MP1.* **E** *Mouse*
histopathology scoring of colon Swiss roles of FMT 1, 3 and 4 from MP2. **F, G** *Mouse transfer experiments from*
FMT 3 and 4: Representative (mean of group) H&E stained sections of colonic Swiss roles and corresponding
higher magnifications for Il10$^{-/-}$ mice (scale bars = 500 µM, HS = histopathology score) respective controls in
Extended Data Fig 3) with Tnf *gene expression levels (fold of control) in distal colon.* **F** *MP1.* **G** *MP2.* **H** *Experimental*
scheme: Patient sample from MP3 is transferred into GF mice (FMT 1) at the age of 8 weeks, for 4 weeks. Same
patient sample is also transferred in an ex vivo *gut chemostat model and treated with EEN-like medium. Fermented*
sample is transplanted (post ex vivo) into GF mice at the age of 8 weeks, for 4 weeks getting either chow diet (FMT
3) or EEN-like purified diet (EEN-like) one week prior to FMT (FMT 4). **I** *MP3 sample for transfer (EEN): patients'*
disease state with wPCDAI and fecal calprotectin, therapy response over time, maintenance therapy (MTX, Anti-
TNF) and sampling time point of transferred fecal sample (blue arrow); grey arrow indicates endoscopy performed
in the patient PostEEN and the picture taken during endoscopy shows active ileitis. **J** *Mouse histopathology scoring*
of colon Swiss roles of FMT 1, 3 and 4 from MP3. **K** *Mouse transfer experiments from FMT 3 and 4 from MP3:*
Representative (mean of group) H&E stained sections of colonic Swiss roles and corresponding higher
magnifications for Il10$^{-/-}$ mice (scale bars = 500 µM, HS = histopathology score) respective controls in Extended
Data Fig 3) with Tnf *gene expression levels (fold of control) in distal colon.* **A, H** *Created with BioRender.com. Data*
*are represented by (**D, E, F, G, J, K**) mean ± SD of six biological replicates. P values were calculated by Mann-*
*Whitney test (**F, G, K**) or two-way ANOVA with Tukey multiple pairwise-comparisons test (**D, E, J**). *p < 0.05, **p <*
*0.01, ***p < 0.001, ****p < 0.0001*

Figure 5

Figure 5: Strains associated with active or inactive disease in Il10⁻/⁻ mice:

A-C *Transfer overview of donor sample (grey) from FMT 1 (black), FMT 3 (EEN-conditioned, blue) and FMT 4 (FR-*

conditioned, brown) into Il10⁻/⁻ mice. Mouse inflammation end-points are shown (triangles, red = active, green =

inactive). Venn diagrams tally strains detected in inflamed (red), non-inflamed (green) Il10⁻/⁻ mice or found in both

*conditions (yellow) for **A** MP1 **B** MP2 **C** MP3 for each FMT and combined FMT 1, 3 and 4. **D-F** LEfSe (Linear*

discriminant analysis Effect Size) analysis of differentially abundant bacteria at species level based on metagenomic

data in the recipient inflamed (active, red) or non-inflamed (inactive, green) Il10⁻/⁻ mice with abundance of strains in

*each condition. Different strains are labeled with different numbers. **D** MP1. **E** MP2. **F** MP3. **G** Venn diagrams shows*

*shared or individual species (left) or strains (right) detected in MP1, MP2 and MP3. *zOTUs found in network*

analyses Fig 1G, S2.

STAR Methods

RESOURCE AVAILABILITY

Lead contact

Further information and requests should be directed to and will be fulfilled by the lead contact Prof. Dr. Dirk Haller (dirk.haller@tum.de).

Materials availability

This study did not generate new unique reagents.

Data and code availability

Data availability
- Some data that support the findings of this study will be available on reasonable request from the corresponding author [TS]. The data are not publicly available due to the pediatric age of the research participants.
- Mouse untargeted metabolomics data is available at Massive (https://massive.ucsd.edu) under the number MSV000094047.
- 16S rRNA gene sequencing results of the cohort, mouse and fermenter experiments will be available at the time of publication.

Code availability
- Mutliomic data integration of 16S rRNA and metabolomics code is available at https://doi.org/10.5281/zenodo.10808412.
- All code necessary to reproduce the metagenomic data analysis will be made publicly available at the time of publication

Experimental model and study participant details

Patient cohort, recruitment and study design

Patients (aged 3-18 years) with suspected or established IBD were recruited to a monocentric pediatric IBD cohort study (ethics approval Ludwig-Maximilians University of Munich, approval No. 17-801 and German Clinical Trials Register Accession No. DRKS00013306, date registration 19.03.2018). All patients and parents/legal guardians provided written informed consent/assent. Patients without confirmed IBD after full diagnostic work-up according to revised Porto criteria were excluded[40]. All other patients were followed prospectively for one

year and treated according to current ESPGHAN/ECCO guidelines for CD or ulcerative colitis

(UC)/IBD unclassified (IBDU)[6,41,42]. Disease activity, as well as endoscopic, histologic,

radiologic and laboratory findings were collected prospectively. Disease activity indices

included the Physician Global Assessment (PGA) and the weighted pediatric Crohn's disease

activity index (wPCDAI) for CD, as well as the pediatric ulcerative colitis activity index (PUCAI)

for UC/IBDU. For EEN-treated CD patients, remission was defined as wPCDAI of <12.5 points

and response as reduction in wPCDAI of >17.5 points, but not reaching remission. Relapse

was defined as increase of wPCDAI to ≥12.5 points and/or fecal calprotectin of >250 mg/L

requiring changes in medical treatment or abdominal surgery or reintroduction of

EEN. Patients received detailed instructions for fecal specimen collections and time points, as

well as stool collection kits. Each sample was accompanied with a questionnaire on date and

time of specimen collection, problems during sampling, Bristol stool scale and recent antibiotic

use.

EEN therapy was prescribed for 6-8 weeks, followed by gradual re-introduction of solid food

and concomitant start of maintenance treatment. EEN was performed with Modulen® IBD

(Nestlé Health Science) or in case of intolerance (e.g. cow's milk protein allergy) with Neocate

Junior® (Nutricia, Erlangen, Germany). The amount of prescribed formula was based on the

Daily   Recommendations   Intake   (DRI)   using   the   online   calculator:

https://www.nal.usda.gov/human-nutrition-and-food-safety/dri-calculator.   All   EEN-treated

patients received dietary advice and dietetic support to comply with complete liquid formula

feeding.

Animal ethics statement

594   All animal experiments were conducted at Technical University of Munich and approved by the

595   Committee on Animal Health Care and Use of the State of Upper Bavaria (TVA ROB-55.2-

596   2532.Vet_02-19-190) and performed in strict compliance with the EEC recommendations for

597   the care and use of laboratory animals (European Communities Council Directive of November

598   24, 1986 (86/609/EEC).

Animals and housing conditions

GF wild-type (WT) and $Il10$-deficient ($Il10^{-/-}$) mice on 129Sv/Ev background were bred and kept

at the Core Facility Gnotobiology of the ZIEL Institute for Food & Health, Technical University

of Munich, Freising, Germany. Mice were housed as described elsewhere[19], but using single

gnoto-cage units (Isocage P System, Tecniplast, Italy). Cages are ventilated with HEPA-

filtered air at 22 ± 1°C with a 12-h light/dark cycle. Female and male mice were assigned

randomly to the treatment groups with a ratio of 1:1 and six mice per genotype. Mice received

standard chow (V1124-300; Ssniff, Soest, Germany; autoclaved) or an EEN-like purified diet

(EEN-like, SNIFF S5745-E902, **Fig. S14D**) and sterile water *ad libitum*. EEN-like diet was

introduced one week prior to fecal microbial transfer (FMT) to allow for adaptation. Handling
of mice in isocages was performed under biological safety cabinets in sterile conditions.

Method details

Fecal specimen collection

Samples were collected at home or in the hospital. Patients provided samples at baseline
(before bowel preparation for endoscopy) and every four weeks in (1) 4 mL DNA stabilizer
(magiX PBI Microbiome Preservation Buffer, microBIOMix GmbH, Regensburg)[43], (2) 8 mL
20% glycerol in reduced phosphate-buffered saline (PBS, 0.05% L-cysteine) and (3) naïve
without stabilizing solution. Patients on EEN collected stool in (1) weekly for the first 12 weeks.
Samples in (1) were shipped at ambient temperature by mail to the study center. Fecal
specimens in (2) and (3) were immediately frozen at home (approx. -18 to -20°C) and brought
in on wet ice packs at the next visit. Upon receipt, samples were aliquoted, barcoded, linked
to clinical data with CentraXX Bio (Kairos GmbH) and stored immediately at -80°C until further
analysis.

Selection of donor samples for BONCAT and transfer experiments into germ-free mice

We selected Stool samples for direct exposure of MCFAs and FMT experiments into germ-
free (GF) mice to show proof-of-concept examples. Therefore, we selected samples based on
sampling timepoint (include various states along EEN therapy: active disease sample from
treatment-naive patient before the start of EEN (PreEEN, pE), EEN-induced remission (EEN,
EE) and a relapse sample after reintroduction of a regular diet (PostEEN, PE)); clinical activity
(pga, calprotectin), drug exposure (shorter time under co-medication preferred) and
histopathology score in Il10$^{-/-}$ mice of FMT1 (direct transfer). For MP1 (model patient 1) the pE
was selected as EE and PE samples induced inflammation in the mouse model, so lowered
disease activity in the patient seemed to be influenced by Anit-TNF. PreEEN sample form MP2
had very bad quality due to its bloody and diarrhetic consistency, therefore EE and relapse
sample were chosen. PE sample in remission was not chosen as a direct impact of EEN
therapy was no longer expected. EE sample from MP3 was chosen to investigate a sample
where mucosal healing was not fully achieved during EEN therapy. Details are in **Table S3**.

Preparing gavage for humanizing germ-free mice

Preparation of FMT with human fecal microbiota was performed according to Metwaly *et al*.
(2020)[19]. For post *ex vivo* FMT, frozen samples in glycerol (20% end concentration) were
thawed on ice. All steps were performed in an anaerobic chamber (90% N_2 and 10% H_2). *Ex*
vivo suspensions (2 mL) were centrifuged at 100×*g* for 3 min at 4°C to pellet debris.
Supernatant was collected and centrifuged at 8000×*g* for 10 min at 4°C to pellet the bacteria.
The bacterial pellet was resuspended in 1.5 mL reduced PBS (0.05% L-cysteine-HCl). The

clear supernatant was transferred into an anaerobic crimped tube, which was transferred to

the gnotobiotic facility. All mice were gavaged on three consecutive days and sacrificed after

four weeks of colonization (12 weeks of age).

Tissue Staining and scoring

Colonic and cecal Swiss-roll tissues were fixed, stained and scored as described before[19]. In

brief, tissue was fixed in 4% formaldehyde/PBS for 48 h at room temperature, subsequently

dehydrated (Leica TP1020), and embedded in paraffin (McCormick; Leica EG1150C).

Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with hematoxylin and

eosin (H&E) and scored 0 (not inflamed) to 12 (highly inflamed). Inflammation cut off was

defined as a histopathology score greater than three based on scoring in WT mice.

Gene expression

Tissue sections from colon were collected in RNAlater (Sigma Aldrich) for 24 h at 4°C and long-

term at -80 °C until processing. Total RNA from tissue was isolated by using the NucleoSpin

RNA II kit (Macherey-Nagel GmbH) according to manufacturer's instructions. Complementary

DNA was synthetized from 500 ng total RNA by using random hexamers and moloney murine

leukemia virus (M-MLV) reverse transcriptase (RT) Point Mutant Synthesis System (Promega).

Quantification was performed by using the LightCycler 480 Universal Probe Library System

(Roche Primers and probes used were: *Gapdh* (glyceraldehyde 3-phosphate dehydrogenase)

(5'-tccactcatggcaaattcaa-3´; 5' tttgatgttagtggggtctcg-3´; Probe #9) and *Tnf* (Tumor necrosis

factor) (5´-tgcctatgtctcagcctcttc 3´; 5´-gaggccatttgggaacttct-3´; Probe #49). Relative induction

of gene mRNA expression was calculated based the 2-ΔΔCt method [44] using the expression

of *Gapdh* for normalization.

***Ex vivo* gut chemostat model**

The *ex vivo* continuous fermentation was performed in 1.4-L bioreactors (Multifors 2) and

monitored with Eve®software (Infors AG, Basel, Switzerland). Parameters were set as

described before[45]. Briefly, vessels were maintained at 37°C, pH 6.8 with a constant influx of

N_2 to maintain an anaerobic atmosphere. Inoculation material was prepared in an anaerobic

chamber (90% N_2 and 10% H_2). Approximately 2.5 g of frozen fecal samples was suspended

in reduced PBS supplemented with 0.03 g/mL L-cysteine-HCl, filtered (70 μm Cell Strainer,

FisherScientific) and evenly distributed between two vessels, which led to about 1.0×10^8 to

8.16×10^8 CFU/vessel. Two consecutive batch fermentations (24 h in 400 mL, another 24 h

with fresh 400 mL medium added) allowed fecal microbial communities to establish.

Continuous fermentation included complete medium exchange every 36 h (retention time) with

a working volume of 400 mL. After 10 days of continuous fermentation, where stable

community formation was achieved, samples for transfer into GF mice were collected and

medium was switched afterwards. After 1.5 days of complete medium exchange from medium

1 to medium 2, samples for transfer into mice were collected on day 9 of continuous
fermentation in the second medium. Medium composition was either fiber-rich (FR) or EEN-
like, mimicking patient conditions at sampling (PreEEN and PostEEN, respectively; **Fig. S8A-**
E).

FR medium was prepared according to Macfarlane *et al*. (1998)[46], but supplemented with
additional vitamins (pantothenate 10 mg/L, nicotinamide 5 mg/L, thiamine 4 mg/L, biotin 2
mg/L, vitamin B12 0.5 mg/L, menadione 1 mg/L, and p-aminobenzoic acid 5 mg/L) as
described in Gibson and Wang[47]. EEN-like medium was based on the Macfarlane medium, but
with modifications simulating colonic-luminal content during an EEN diet. To determine the
carbohydrate:protein ratio of digested Modulen IBD® in the colon, similar calculations as
described previously were conducted[48,49]. Since Modulen IBD® lacks fibers, these ingredients
present in the FR medium (i.e., pectin from citrus, guar gum, xylan from oat spelt, inulin from
Dahlia tubers, and arabinogalactan from larch wood) were replaced by soluble rice starch and
simple sugars. A total carbohydrate concentration of 13 g/L was chosen in alignment with
Cinquin *et al.* (2004)[48]. As the formulation of Modulen IBD® is not publicly available, we
decided to include some Modulen IBD® not to miss crucial nutrients in our model-colon
medium. Towards this end, 10% of the 1kcal/mL standard preparation of Modulen IBD® was
added to 1L of EEN-like medium. Finally, the carbohydrate:protein ratio was 75:25 in the model
medium. To further mimic Modulen IBD®, casein was used as main protein source with the
exclusion of tryptone and peptone (**Fig. S14A-C**).

Samples were aseptically collected daily at the same daytime and stored at -80°C until further
analyses. Samples for transfer into the GF mice were collected and mixed with glycerol (20%
end concentration) and stored at -80°C until gavage preparation. In order to diminish potential
vessel effects in the technical duplicates of each fermenter colonization, samples from both
vessels were mixed 50:50 for gavage.

High-throughput 16S-ribosomal RNA (rRNA) gene amplicon sequencing analysis
Total DNA from human stool, colonic mouse content and the continuous *ex vivo* fermentation
was isolated using bead beating and sequenced for 16S rRNA gene amplicons as described[50].
Downstream analysis was performed in R v4.2.1 using Rhea
(https://lagkouvardos.github.io/Rhea/)[51]. zOTU tables were normalized to 10.000 reads, beta-
diversity was computed using generalized UniFrac distances[52]. Alpha-diversity was assessed
on the basis of taxa richness and Shannon effective number of zOTUs[53]. Trees were visualized
and annotated using EvolView (http://www.evolgenius.info/evolview/)[54]. Differential analyses
of bacteria in different groups was done using LDA Effect Size (LEfSe)[55]. zOTUs were re-
checked using the 16S-based ID tool of EzBioCloud[56] using the database update 2023.08.23,
reflecting all taxa published and accepted by IJSEM until April 2023.

Shotgun Metagenomic Sequencing and Analysis

Metagenomic sequencing was performed for 96 human stool samples and 66 samples from transfer experiments (54 mouse, 12 *ex vivo*) using the genomic DNA already isolated for 16S rRNA gene amplicon sequencing. DNA was randomly sheared into short fragments. The obtained fragments were end repaired, A-tailed, and further ligated with Illumina adapters. The fragments with adapters were size-selected, PCR amplified, and purified. The library was checked with Qubit and real-time PCR for quantification and BioAnalyzer for size distribution detection as required by Illumina (TruSeq® DNA Library Prep Kit). Quantified libraries were pooled and sequenced on a NovaSeq platform (Illumina) in PE150 mode. Raw data were aimed at 15 Gb per demultiplexed sample. From raw shotgun metagenomic sequencing data, adapter sequences were removed using Trimmomatic v0.39[57] without considering any mismatch and parameters LEADING:3, TRAILING:3, and SLIDINGWINDOW:4:15. We removed human reads by mapping against human reference genome hg38 by using Bowtie2 v2.4.5 [58] with the default parameters. Cleaned fastq data files were used in the following steps.

Strain tracking and strain gene content analyses were performed based on the StrainPGC workflow[59]. Briefly, preprocessed metagenomes were metagenotyped using GT-Pro v1.0.1[60]. Across all samples, 369 species - as defined in the Unified Human Gut Genome (UHGG)[61] - were robustly detected and only these were included in downstream pangenome profiling. Single nucleotide polymorphism (SNP) profiles were filtered, subsampled, and strain relative abundances were estimated with StrainFacts v0.4.0[18]. Within individual species, estimated strain fractions add up to 100%. By contrast, other analyses considered the overall strain composition: the relative abundance of each strain across all species.

Gene profiling was performed against a subset of the MIDASDB-UHGG pangenome database v.15[62] dereplicated at a 99% ANI threshold performed and mapping reads using Bowtie2 v2.4.5[58]. Species abundances were estimated based on the average depth of core genes. Global functional gene family profiling was performed by aggregating gene depths into Clusters of Orthologous Genes (COGs) across all species and then normalizing based on 25 ubiquitous, single-copy genes to estimate "gene copies per genome".

***Ex vivo* anaerobic incubations with medium chain fatty acids (MCFAs)**

Fecal samples (MP1 PreEEN, MP2 EEN, MP2 relapse, and MP3 EEN) previously collected in 20% glycerol in reduced phosphate-buffered saline (PBS, 0.05% L-cysteine) were thawed and introduced into an anaerobic chamber (10% H_2, 90% N_2). All reagents and materials were introduced in the anaerobic chamber 48 hours before sample processing to ensure anaerobic state by the start of the experiment.

Stool samples (1-1,5 g) were homogenized with 1X PBS (1:10 dilution) and filtered using a 40 μm size filter (Corning, Germany) to remove large particles, which was followed by three

washing steps in 1X sterile PBS to remove residual of glycerol and leftover nutrients in the

stool. Afterwards, samples were added to sterile falcon tubes containing a final concentration

of 50µM of the cellular activity marker L-azidohomoalanine (AHA), (Baseclick GmbH,

Germany) and 10µM of MCFAs (lauric acid, decanoid acid and octanoic acid) dissolved in

ethanol with a final concentration of 0.5%. 0.5% ethanol was used as negative control and 2

mg/mL of glucose as positive control for each experiment. Samples were incubated for 24

hours under anaerobic conditions. After 24 hours of incubation, part of the samples were frozen

for DNA extraction and other aliquots were washed twice in PBS and then fixed in 1:1

ethanol:PBS for further analysis with fluorescence activated cell sorting (FACS). Both ethanol

fixed and frozen samples were collected in triplicates[63,64].

Bioorthogonal non-canonical amino acid tagging (BONCAT) and images analysis of

translationally active bacteria

To identify utilization capability of MCFAs by the gut microbiota, we employed BONCAT, a

fluorescence-based single cell labeling technique. BONCAT involves incorporation of the non-

canonical amino acid AHA to replace L-methionine during protein synthesis, followed by

fluorescent labeling of AHA-containing proteins using azide-alkyne click chemistry[65] (**Fig. 2A**).

Cu(I)-catalyzed click chemistry reaction was performed on microscopy slides as previously

described[65] and counter-stained with 4′, 6-diamidino-2-phenylindole (DAPI).

20 pictures for each sample were collected using a confocal microscope (Olympus, fluoview,

FV10i, Germany) and processed using Fiji[66]. Translationally active cells were quantified using

the software *digital image analysis in microbial ecology* (Daime)[67]. Translationally active cells

were measured as biovolume fraction comparing the Cy5-labeled cells (BONCAT positive) to

the total biomass stained with DAPI.

BONCAT-FACS and DNA extraction

A combination of BONCAT and FACS was used to determine which bacteria are capable of

MCFAs utilization. Briefly, ethanol fixed samples were washed in 1X sterile PBS, resuspended

in 96% ethanol and centrifuged again. Afterwards, the BONCAT dye solution was added to the

samples and incubated for 30 min in the dark at room temperature[65]. After incubation, samples

were washed three time in 1X sterile PBS and filtered with a 35 mm nylon mesh using BD

tubes 12x 75 mm (Corning, Germany) right before sorting. Cy5-positive bacteria were sorted,

collected into sterile tubes and store at-80°C until DNA extraction. A representation of the

gating strategy is shown in Supplementary Figures 1.

Bacterial DNA from sorted and unsorted samples were extracted using the QIAmp DNA mini

kit (Qiagen, Germany) following the protocols for bacteria according to the manufacturer's

instructions with an additional lysozyme treatment[64]. Every sample was sorted in triplicates.

FACS data were further analyzed with FlowJo™ v10.10.0 Software (BD Life Sciences;

Reference: FlowJo™ Software (for Windows) Version v10.10.0. Ashland, OR: Becton,
Dickinson and Company; 2023).

BONCAT data analysis

Statistical analysis was performed using R statistical software (https://www.r-project.org/). 16S
rRNA amplicon sequencing analysis was carried out with Rhea, beta diversity was assessed
using UniFrac distances as previously described [51,52] and the statistical significance of factors
was evaluated using permutational multivariate analysis of variance (perMANOVA).
Differences in relative abundance between sorted and unsorted fractions and between sorted
MCFAs and ethanol control, were analyzed using ANOVA and Tukey's test for multiple
comparisons. For quantifications of the percentage of active cells, Kruskal-Wallis and Dunn's
test were applied. Significantly enriched and depleted zOTUs sequences were identified using
the 16S-based ID tool of EzBioCloud[56].

799
Metabolomics

Sample preparation / Metabolites extraction
Sample preparation of mouse colon content. Approximately 20 mg of mouse colon content
was weighed in a 2 mL bead beater tube (FastPrep-Tubes, Matrix D, MP Biomedicals Germany
GmbH, Eschwege, Germany). Next, 1 mL of methanol-based dehydrocholic acid extraction
solvent (c = 1.3 µmol/L) was added as an internal standard for work-up losses. The samples
were extracted with a bead beater FastPep-24TM 5G (MP Biomedicals Germany GmbH,
Eschwege, Germany) supplied with a CoolPrepTM (MP Biomedicals Germany, cooled with dry
ice) 3-times each for 20 s of beating at a speed of 6 m/s and followed by a break of 30 s each.
Sample preparation of fermenter or human samples. Either 200 mg of the fermenter
samples or 100 mg of human fecal samples was weighed in a 15 mL bead beater tube
(FastPrep-Tubes, Matrix D, MP Biomedicals Germany GmbH, Eschwege, Germany). Next,
5 mL of methanol-based dehydrocholic acid extraction solvent (c = 1.3 µmol/L) was added as
an internal standard for work-up losses. The samples were extracted with the same FastPrep
protocol described above.
Targeted bile acid measurement. A standard of 20 µL of isotopically labeled bile acids (ca. 7
µM each) were added to 100 µL of sample extract. Targeted bile acid measurement was
performed using a QTRAP 5500 triple quadrupole mass spectrometer (Sciex, Darmstadt,
Germany) coupled to an ExionLC AD (Sciex, Darmstadt, Germany) ultrahigh performance
liquid chromatography system. A multiple reaction monitoring (MRM) method was used for the
detection and quantification of the bile acids according to Reiter et. al.[68] Data acquisition and
instrumental control were performed with Analyst v1.7 software (Sciex, Darmstadt, Germany).
Untargeted mass spectrometric measurement. The untargeted analysis was performed
using a Nexera UHPLC system (Shimadzu, Duisburg, Germany) coupled to a Q-TOF mass

spectrometer (TripleTOF 6600, AB Sciex, Darmstadt, Germany). Separation of the fecal

samples was performed either using a UPLC BEH Amide 2.1 × 100 mm, 1.7 µm analytic

column (Waters, Eschborn, Germany) with a 400 µL/min flow rate or with a Kinetex XB18 2.1

x 100 mm, 1.7 µm (Phenomenex, Aschaffenburg, Germany) with a 300 µL/min flow rate. For

the HILIC-separation the settings were as follows: The mobile phase was 5 mM ammonium

acetate in water (eluent A) and 5 mM ammonium acetate in acetonitrile/water (95/5, v/v) (eluent

B). The gradient profile was 100% B from 0 to 1.5 min, 60% B at 8 min and 20% B at 10 min to

11.5 min and 100% B at 12 to 15 min. For the reversed-phase separation, eluent A was 0.1%

formic acid and eluent B was 0.1% formic acid in acetonitrile. The gradient profile started with

0.2% B which was held for 0.5 min. Afterwards, the concentration of eluent B was increased

to 100% until 10 min which was held for 3.25 min. Subsequently, the column was equilibrated

at starting conditions. A volume of 5 µL per sample was injected. The autosampler was cooled

to 10 °C and the column oven heated to 40 °C. Every tenth run, a quality control (QC) sample,

which was pooled from all samples, was injected. The samples were measured in a

randomized order and in the Information Dependent Acquisition (IDA) mode. MS settings in

the positive mode were as follows: Gas 1 55, Gas 2 65, Curtain gas 35, Temperature 500 °C,

Ion Spray Voltage 5500, declustering potential 80. The mass range of the TOF MS and MS/MS

scans were 50–2000 m/z and the collision energy was ramped from 15–55 V. MS settings in

the negative mode were as follows: Gas 1 55, Gas 2 65, Cur 35, Temperature 500 °C, Ion

Spray Voltage -4500, declustering potential -80. The mass range of the TOF MS and MS/MS

scans were 50–2000 m/z and the collision energy was ramped from -15–55 V.

Data processing

The "msconvert" from ProteoWizard[69] was used to convert raw files to mzXML (de-noised by

centroid peaks). The bioconductor/R package xcms[70] was used for data processing and

feature identification. More specifically, the matchedFilter algorithm was used to identify peaks

(full width at half-maximum set to 7.5 s). Then the peaks were grouped into features using the

"peak density" method[70]. The area under the peak was integrated to represent the abundance

of features. The retention time was adjusted based on the peak groups presented in most

samples. To annotate features with names of metabolites, the exact mass and MS2

fragmentation pattern of the measured features were compared to the records in HMBD[71] and

the public MS/MS spectra in MSDIAL[72], referred to as MS1 and MS2 annotation, respectively.

Missing values were imputed with half of the limit of detection (LOD) methods, i.e., for every

feature, the missing values were replaced with half of the minimal measured value of that

feature in all measurements. To confirm a MS2 spectra is well annotated, we manually

reviewed our MS2 fragmentation pattern and compared it with records in the public database,

previously measured reference standards and SIRIUS[73] to evaluate the correctness of the

annotation. Significances of well-annotated metabolic features were computed with analysis

of variance (ANOVA) per donor or Wilcoxon signed-rank tests and FDR-corrected using the

Benjamin-Hochberg method for three donors. Subsequent hierarchical clustering using only

differentially abundant metabolites (q < 0.05) was conducted using complete linkage based on

Euclidean distances. Calculations, as well as heatmaps, were computed in R v4.2.1. For each

principal component analysis (PCA), we included negative and positive features from RP and

HILIC with at least 50% non-missing values per condition (inflamed/non-inflamed). The

remaining missing values were imputed as described above. The prcomp function from R

v4.3.2 computed the principal components after centering and scaling each feature to zero

mean and unit variance. Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) was

performed on centered and scaled features using the mixOmics bioconductor/R package

v6.26.0(Singh et al., 2019). Mean balanced error rate, was used to select the number of

components and features in M-fold cross-validation where M corresponds to the minimum

number of samples per condition. **Fig. S11** shows raw values for features with the highest

Variable Importance in the Projection (VIP), i.e., features contributing the most to explaining

the conditions.

Data integration of 16s rRNA amplicon data with metabolomics and metagenomics

We matched 60 samples from 15 patients of the 16S-rRNA gene sequencing to 60 samples of

the untargeted metabolomics analysis according to patient ID and same time points. The aim

was to select features that jointly discriminate the 23 EEN samples (clinical phenotype mild

and remission) and 37 PostEEN samples (>2 weeks after EEN, clinical remission). For the

integrated selection of metabolome and microbiota features, sPLS-DA (mixOmics v6.20) was

used(Singh et al., 2019). For feature selection concerning metabolomics, only annotated

metabolites were considered. As described above, input metabolites were mean-centered and

scaled to unit variance. zOTUs (zero-radius operational taxonomic units) were centered log-

ratio transformed. To estimate the degree of overfitting, the model was trained on 70% of the

data, with a k-fold cross-validation for feature selection during training. The remaining 30% of

the data were used to evaluate the generalization power. The model performance was

measured with an Area Under the Receiver Operating Characteristic (ROC-AUC) on the

samples in the test set. Subsequently, Spearman's rank correlation coefficients between all

selected metabolites and zOTUs were computed and their respective p-values were corrected

with the Benjamini-Hochberg procedure[75]. All coefficients with an FDR >0.05 were set to 0.

Using all non-zero correlations, a network was generated and the Louvain method for

community detection[76] was applied to extract highly connected subgraphs from the correlation

network. For each community, a sPLS-DA model was trained with the same train-test scheme

explained previously for feature selection. Using the mean loadings scores over all k iterations,

the most relevant metabolites and zOTUs were identified. More precisely, for metabolites and

zOTUs separately, the absolute mean loadings were plotted in ascending order and all features

on the right of the knee point (20 zOTUs and 22 metabolites) were selected. Analyses were

run in R v4.2.1 and python v3.8.11. For network analysis the igraph v1.3.4[77] and networkx

v3.1[78] packages were used.

Profiles of 16S rRNA amplicon relative abundance were further integrated with metagenomic

species profiles in order to identify those which represent the same, underlying taxa. This was

done by cross-decomposition of zOTU relative abundance and species relative abundances

estimated from the metagenomic workflow, using the PLSSVD model implemented in SciKit-

Learn[79], multiplying the matrices of weights for each data-type provides a matrix of coefficients

mapping zOTUs to metagenomic species. We scaled these coefficients by the square-root of

the mean relative abundance of that zOTU and species, respectively, producing a matrix of

matching scores for each comparison, while accounting for all other taxa. Based on this score,

we ranked zOTUs for each species and species for each zOTU. We selected as putative

matches all zOTU-species pairs that were either reciprocal best hits or a combination of one

best hit and one second-best hit, and where at least one of the genus or family classifications

matched. In this way, we accounted for the possibility of multiple zOTUs representing a species

or multiple species being represented by a zOTU.

Statistical analysis

MDS and PCA latent dimensions in **Fig. 1** and **Fig. S1** were tested for significance using linear

mixed models of the form

918   axis ~ intercept + diet + disease + diet * disease + (1|patient)

where diet, disease and their interaction are included as fixed effects and patients are included

as random effects. All coefficients are tested with a t-test for **Fig. 1** and an ANOVA for **Fig. S1**.

Reported p-values are Bonferroni-corrected. To estimate the degrees of freedom, we used

Satterthwaite's method as implemented in the lmerTest package (version 3.1-3).

Further statistical analyses and plots were generated using GraphPad Prism v8.0 (GraphPad,

La Jolla, CA) using Mann-Whitney test, ANOVA followed by pairwise comparison testing

(Tukey, Bonferroni correction), by Kruskal-Wallis test followed by Dunn`s multiple comparisons.

Data is presented as mean ± SD. P-values below 0.05 were considered significant ($p < 0.05$,

*; $p < 0.01$, **; $p < 0.001$, ***; and $p < 0.0001$, ****).

Taxonomic turnover in both zOTU and strain compositions were calculated based on the Bray-

Curtis dissimilarity. Pairs where one sample was collected during EEN and the other during

PostEEN were classified as "transition". All within-subject pairwise comparisons were

computed and fit using cubic spline regression of the time between sample collections, with a

regression term for each subject, as well as for each pair class: EEN, transition, or PostEEN.
The null hypothesis of no difference between pair classes was tested by permutation: 999
random permutations of samples within subjects. Changes in mean, normalized, COG depths
during EEN and PostEEN time points were tested using the Wilcoxon signed-rank test across
subjects. False discovery rates were calculated using the Benjamini-Hochberg procedure.
Mean fold change for each COG was calculated as the ratio between these two estimates.

Additional resources

Clinical Trial Registry

The study is registered at the German Clinical Trials Registry under the Accession No.
DRKS00013306, date of registration 19.03.2018.

Supplementary Data

Supplemental information.

Document S1. Figures S1-S14, Tables S1-S5:

Figures S1-S3 related to Figure 1.

Tables S1- S2 related to Figure 1.

Table S3 related to donor sample selection related to Figure 2 -5

Figures S4-S5 and tables S4-S5 related to Figure 2

Figures S6 and tables S6 and S7 are related to Figure 3.

Figures S7-S8 related to Figure 4.

Figures S9-S13 related to Figure 5.

Figures S14 related to media and diet information in STARMethods.

Tables S6 and S7: Excel files containing additional data too large to fit in a PDF. Related to

Figure 3.

References

1. Torres, J., Mehandru, S., Colombel, J.F., and Peyrin-Biroulet, L. (2017). Crohn's disease. Lancet *389*, 1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1.

2. Kuenzig, M.E., Fung, S.G., Marderfeld, L., Mak, J.W.Y., Kaplan, G.G., Ng, S.C., Wilson, D.C., Cameron, F., Henderson, P., Kotze, P.G., et al. (2022). Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology *162*, 1147-1159.e4. https://doi.org/10.1053/j.gastro.2021.12.282.

3. Kaplan, G.G., and Ng, S.C. (2017). Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology *152*, 313-321.e2. https://doi.org/10.1053/j.gastro.2016.10.020.

4. Liu, Z., Liu, R., Gao, H., Jung, S., Gao, X., Sun, R., Liu, X., Kim, Y., Lee, H.S., Kawai, Y., et al. (2023). Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet *55*, 796. https://doi.org/10.1038/S41588-023-01384-0.

5. Renz, H., Von Mutius, E., Brandtzaeg, P., Cookson, W.O., Autenrieth, I.B., and Haller, D. (2011). Gene-environment interactions in chronic inflammatory disease. Nature Immunology 2011 12:4 *12*, 273–277. https://doi.org/10.1038/ni0411-273.

6. Van Rheenen, P.F., Aloi, M., Assa, A., Bronsky, J., Escher, J.C., Fagerberg, U.L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2020). The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis *15*, 171–194. https://doi.org/10.1093/ECCO-JCC/JJAA161.

7. Agrawal, M., Spencer, E.A., Colombel, J.-F., and Ungaro, R.C. (2021). Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology *161*, 47–65. https://doi.org/10.1053/j.gastro.2021.04.063.

8. Bischoff, S.C., Bager, P., Escher, J., Forbes, A., Hébuterne, X., Hvas, C.L., Joly, F., Klek, S., Krznaric, Z., Ockenga, J., et al. (2023). ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. Clinical Nutrition *42*, 352–379. https://doi.org/10.1016/j.clnu.2022.12.004.

9. Logan, M., Gkikas, K., Svolos, V., Nichols, B., Milling, S., Gaya, D.R., Seenan, J.P., Macdonald, J., Hansen, R., Ijaz, U.Z., et al. (2020). Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease—new insights into dietary disease triggers. Aliment Pharmacol Ther *51*, 935–947. https://doi.org/10.1111/APT.15695.

10. Logan, M., Clark, C.M., Ijaz, U.Z., Gervais, L., Duncan, H., Garrick, V., Curtis, L., Buchanan, E., Cardigan, T., Armstrong, L., et al. (2019). The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharmacol Ther *50*, 664. https://doi.org/10.1111/APT.15425.

11. Schwerd, T., Frivolt, K., Clavel, T., Lagkouvardos, I., Katona, G., Mayr, D., Uhlig, H.H., Haller, D., Koletzko, S., and Bufler, P. (2016). Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. Journal

998 of Allergy and Clinical Immunology *138*, 592–596.
999 https://doi.org/10.1016/j.jaci.2015.12.1331.

12. Frivolt, K., Schwerd, T., Werkstetter, K.J., Schwarzer, A., Schatz, S.B., Bufler, P., and Koletzko, S. (2014). Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: Predictors of efficacy and outcome. Aliment Pharmacol Ther *39*, 1398–1407. https://doi.org/10.1111/apt.12770.

13. Metwaly, A., Reitmeier, S., and Haller, D. (2022). Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nature Reviews Gastroenterology & Hepatology 2022 19:6 *19*, 383–397. https://doi.org/10.1038/s41575-022-00581-2.

14. Schirmer, M., Garner, A., Vlamakis, H., and Xavier, R.J. (2019). Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol *17*, 497. https://doi.org/10.1038/S41579-019-0213-6.

15. Lavelle, A., and Sokol, H. (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2020 17:4 *17*, 223–237. https://doi.org/10.1038/s41575-019-0258-z.

16. Pereira, G.V., Boudaud, M., Wolter, M., Alexander, C., De Sciscio, A., Grant, E.T., Trindade, B.C., Pudlo, N.A., Singh, S., Campbell, A., et al. (2024). Opposing diet, microbiome, and metabolite mechanisms regulate inflammatory bowel disease in a genetically susceptible host. Cell Host Microbe *32*, 527-542.e9. https://doi.org/10.1016/j.chom.2024.03.001.

17. Tanes, C., Bittinger, K., Gao, Y., Friedman, E.S., Nessel, L., Paladhi, U.R., Chau, L., Panfen, E., Fischbach, M.A., Braun, J., et al. (2021). Role of dietary fiber in the recovery of the human gut microbiome and its metabolome. Cell Host Microbe *29*, 394-407.e5. https://doi.org/10.1016/j.chom.2020.12.012.

18. Smith, B.J., Li, X., Shi, Z.J., Abate, A., and Pollard, K.S. (2022). Scalable Microbial Strain Inference in Metagenomic Data Using StrainFacts. Frontiers in Bioinformatics *2*. https://doi.org/10.3389/fbinf.2022.867386.

19. Metwaly, A., Dunkel, A., Waldschmitt, N., Raj, A.C.D., Lagkouvardos, I., Corraliza, A.M., Mayorgas, A., Martinez-Medina, M., Reiter, S., Schloter, M., et al. (2020). Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolism. Nature Communications 2020 11:1 *11*, 1–15. https://doi.org/10.1038/s41467-020-17956-1.

20. Jiang, J., Chen, L., Chen, Y., and Chen, H. (2022). Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn's disease. BMC Gastroenterol *22*. https://doi.org/10.1186/S12876-022-02293-Y.

21. Vich Vila, A., Imhann, F., Collij, V., Jankipersadsing, S.A., Gurry, T., Mujagic, Z., Kurilshikov, A., Bonder, M.J., Jiang, X., Tigchelaar, E.F., et al. (2018). Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med *10*. https://doi.org/10.1126/scitranslmed.aap8914.

22. Podlesny, D., Durdevic, M., Paramsothy, S., Kaakoush, N.O., Högenauer, C., Gorkiewicz, G., Walter, J., and Fricke, W.F. (2022). Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Rep Med *3*, 100711. https://doi.org/10.1016/j.xcrm.2022.100711.

23. Yang, H.T., Chen, J.W., Rathod, J., Jiang, Y.Z., Tsai, P.J., Hung, Y.P., Ko, W.C., Paredes-
Sabja, D., and Huang, I.H. (2018). Lauric acid is an inhibitor of Clostridium difficile
growth in vitro and reduces inflammation in a mouse infection model. Front Microbiol *8*,
2635. https://doi.org/10.3389/FMICB.2017.02635/FULL.

24. Kabara, J.J., Swieczkowski, D.M., Conley, A.J., and Truant, J.P. (1972). Fatty acids and
derivatives as antimicrobial agents. Antimicrob Agents Chemother *2*, 23–28.
https://doi.org/10.1128/AAC.2.1.23.

25. Huang, W.C., Tsai, T.H., Chuang, L. Te, Li, Y.Y., Zouboulis, C.C., and Tsai, P.J. (2014).
Anti-bacterial and anti-inflammatory properties of capric acid against Propionibacterium
acnes: A comparative study with lauric acid. J Dermatol Sci *73*, 232–240.
https://doi.org/10.1016/j.jdermsci.2013.10.010.

26. Sorrentino, G., Perino, A., Yildiz, E., El Alam, G., Bou Sleiman, M., Gioiello, A.,
Pellicciari, R., and Schoonjans, K. (2020). Bile Acids Signal via TGR5 to Activate
Intestinal Stem Cells and Epithelial Regeneration. Gastroenterology *159*, 956-968.e8.
https://doi.org/10.1053/j.gastro.2020.05.067.

27. Xiao, F., Gao, X., Hu, H., Le, J., Chen, Y., Shu, X., Liang, Z., Xu, Y., Wang, Y., and Zhang,
T. (2022). Exclusive Enteral Nutrition Exerts Anti-Inflammatory Effects through
Modulating Microbiota, Bile Acid Metabolism, and Immune Activities. Nutrients *14*, 4463.
https://doi.org/10.3390/NU14214463/S1.

28. Lv, Y., Lou, Y., Liu, A., Cheng, Q., Yang, G., Xu, C., Luo, Y., Lou, J., Yu, J., Fang, Y., et
al. (2023). The impact of exclusive enteral nutrition on the gut microbiome and bile acid
metabolism in pediatric Crohn's disease. Clinical Nutrition *42*, 116–128.
https://doi.org/10.1016/j.clnu.2022.11.018.

29. Gill, S.K., Rossi, M., Bajka, B., and Whelan, K. (2020). Dietary fibre in gastrointestinal
health and disease. Nature Reviews Gastroenterology & Hepatology 2020 18:2 *18*,
101–116. https://doi.org/10.1038/s41575-020-00375-4.

30. Schroeder, B.O., Birchenough, G.M.H., Ståhlman, M., Arike, L., Johansson, M.E.V.,
Hansson, G.C., and Bäckhed, F. (2018). Bifidobacteria or Fiber Protects against Diet-
Induced Microbiota-Mediated Colonic Mucus Deterioration. Cell Host Microbe *23*, 27-
40.e7. https://doi.org/10.1016/j.chom.2017.11.004.

31. Desai, M.S., Seekatz, A.M., Koropatkin, N.M., Kamada, N., Hickey, C.A., Wolter, M.,
Pudlo, N.A., Kitamoto, S., Terrapon, N., Muller, A., et al. (2016). A Dietary Fiber-Deprived
Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen
Susceptibility. Cell *167*, 1339-1353.e21. https://doi.org/10.1016/j.cell.2016.10.043.

32. Haskey, N., Gold, S.L., Faith, J.J., and Raman, M. (2023). To Fiber or Not to Fiber: The
Swinging Pendulum of Fiber Supplementation in Patients with Inflammatory Bowel
Disease. Nutrients 2023, Vol. 15, Page 1080 *15*, 1080.
https://doi.org/10.3390/NU15051080.

33. Armstrong, H., Mander, I., Zhang, Z., Armstrong, D., and Wine, E. (2021). Not All Fibers
Are Born Equal; Variable Response to Dietary Fiber Subtypes in IBD. Front Pediatr *8*,
620189. https://doi.org/10.3389/fped.2020.620189.

34. Armstrong, H.K., Bording-Jorgensen, M., Santer, D.M., Zhang, Z., Valcheva, R., Rieger,
A.M., Sung-Ho Kim, J., Dijk, S.I., Mahmood, R., Ogungbola, O., et al. (2023).

Unfermented β-fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease
Patients. Gastroenterology *164*, 228–240. https://doi.org/10.1053/j.gastro.2022.09.034.

35. Arifuzzaman, M., Won, T.H., Li, T.T., Yano, H., Digumarthi, S., Heras, A.F., Zhang, W.,
Parkhurst, C.N., Kashyap, S., Jin, W.B., et al. (2022). Inulin fibre promotes microbiota-
derived bile acids and type 2 inflammation. Nature 2022 611:7936 *611*, 578–584.
https://doi.org/10.1038/s41586-022-05380-y.

36. Singh, V., Yeoh, B.S., Walker, R.E., Xiao, X., Saha, P., Golonka, R.M., Cai, J., Bretin,
A.C.A., Cheng, X., Liu, Q., et al. (2019). Microbiota fermentation-NLRP3 axis shapes
the impact of dietary fibres on intestinal inflammation. Gut *68*, 1801–1812.
https://doi.org/10.1136/GUTJNL-2018-316250.

37. Kuffa, P., Pickard, J.M., Campbell, A., Yamashita, M., Schaus, S.R., Martens, E.C.,
Schmidt, T.M., Inohara, N., Núñez, G., and Caruso, R. (2023). Fiber-deficient diet
inhibits colitis through the regulation of the niche and metabolism of a gut pathobiont.
Cell Host Microbe. https://doi.org/10.1016/J.CHOM.2023.10.016.

38. Metwaly, A., Jovic, J., Waldschmitt, N., Khaloian, S., Heimes, H., Häcker, D., Ahmed,
M., Hammoudi, N., Le Bourhis, L., Mayorgas, A., et al. (2023). Diet prevents the
expansion of segmented filamentous bacteria and ileo-colonic inflammation in a model
of Crohn's disease. Microbiome *11*, 66. https://doi.org/10.1186/s40168-023-01508-y.

39. Turner, D., Ricciuto, A., Lewis, A., D'Amico, F., Dhaliwal, J., Griffiths, A.M., Bettenworth,
D., Sandborn, W.J., Sands, B.E., Reinisch, W., et al. (2021). STRIDE-II: An Update on
the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of
the International Organization for the Study of IBD (IOIBD): Determining Therapeutic
Goals for Treat-to-Target strategies in IBD. Gastroenterology *160*, 1570–1583.
https://doi.org/10.1053/J.GASTRO.2020.12.031.

40. Levine, A., Koletzko, S., Turner, D., Escher, J.C., Cucchiara, S., de Ridder, L., Kolho,
K.-L., Veres, G., Russell, R.K., Paerregaard, A., et al. (2014). ESPGHAN Revised Porto
Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents.
J Pediatr Gastroenterol Nutr *58*, 795–806.
https://doi.org/10.1097/MPG.0000000000000239.

41. Turner, D., Ruemmele, F.M., Orlanski-Meyer, E., Griffiths, A.M., De Carpi, J.M., Bronsky,
J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C.P., et al. (2018). Management of
paediatric ulcerative colitis, part 1: Ambulatory Care-An Evidence-based Guideline From
European Crohn's and Colitis Organization and European Society of Paediatric
Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr *67*, 257–291.
https://doi.org/10.1097/MPG.0000000000002035.

42. Turner, D., Ruemmele, F.M., Orlanski-Meyer, E., Griffiths, A.M., De Carpi, J.M., Bronsky,
J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C.P., et al. (2018). Management of
paediatric ulcerative colitis, part 2: Acute severe colitis - An evidence-based consensus
guideline from the european Crohn's and colitis organization and the european society
of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr
67, 292–310. https://doi.org/10.1097/MPG.0000000000002036.

43. Schult, D., Reitmeier, S., Koyumdzhieva, P., Lahmer, T., Middelhof, M., Erber, J.,
Schneider, J., Kager, J., Frolova, M., Horstmann, J., et al. (2022). Gut bacterial dysbiosis

and instability is associated with the onset of complications and mortality in COVID-19.
Gut Microbes *14*. https://doi.org/10.1080/19490976.2022.2031840.

44. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of Relative Gene Expression Data
Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods *25*, 402–408.
https://doi.org/10.1006/METH.2001.1262.

45. Püngel, D., Treveil, A., Dalby, M.J., Caim, S., Colquhoun, I.J., Booth, C., Ketskemety,
J., Korcsmaros, T., van Sinderen, D., Lawson, M.A., et al. (2020). Bifidobacterium breve
UCC2003 Exopolysaccharide Modulates the Early Life Microbiota by Acting as a
Potential Dietary Substrate. Nutrients *12*, 948. https://doi.org/10.3390/nu12040948.

46. Macfarlane, G.T., Macfarlane, S., and Gibson, G.R. (1998). Validation of a three-stage
compound continuous culture system for investigating the effect of retention time on the
ecology and metabolism of bacteria in the human colon. Microb Ecol *35*, 180–187.
https://doi.org/10.1007/s002489900072.

47. Gibson, G.R., and Wang, X. (1994). Enrichment of bifidobacteria from human gut
contents by oligofructose using continuous culture. FEMS Microbiol Lett *118*, 121–127.
https://doi.org/10.1016/0378-1097(94)90606-8.

48. Cinquin, C., Le Blay, G., Fliss, I., and Lacroix, C. (2004). Immobilization of infant fecal
microbiota and utilization in an in vitro colonic fermentation model. Microb Ecol *48*, 128–
138. https://doi.org/10.1007/s00248-003-2022-7.

49. Poeker, S.A., Lacroix, C., de Wouters, T., Spalinger, M.R., Scharl, M., and Geirnaert, A.
(2019). Stepwise Development of an in vitro Continuous Fermentation Model for the
Murine   Caecal   Microbiota.   Front   Microbiol   *10*.
https://doi.org/10.3389/fmicb.2019.01166.

50. Reitmeier, S., Kiessling, S., Neuhaus, K., and Haller, D. (2020). Comparing Circadian
Rhythmicity   in   the   Human   Gut   Microbiome.   STAR   Protoc   *1*,   100148.
https://doi.org/10.1016/j.xpro.2020.100148.

51. Lagkouvardos, I., Fischer, S., Kumar, N., and Clavel, T. (2017). Rhea: a transparent and
modular R pipeline for microbial profiling based on 16S rRNA gene amplicons. PeerJ *5*,
e2836. https://doi.org/10.7717/peerj.2836.

52. Chen, J., Bittinger, K., Charlson, E.S., Hoffmann, C., Lewis, J., Wu, G.D., Collman, R.G.,
Bushman, F.D., and Li, H. (2012). Associating microbiome composition with
environmental covariates using generalized UniFrac distances. Bioinformatics *28*,
2106–2113. https://doi.org/10.1093/bioinformatics/bts342.

53. Jost, L. (2007). Partitioning diversity into independent alpha and beta components.
Ecology *88*, 2427–2439. https://doi.org/10.1890/06-1736.1.

54. Subramanian, B., Gao, S., Lercher, M.J., Hu, S., and Chen, W.H. (2019). Evolview v3:
a webserver for visualization, annotation, and management of phylogenetic trees.
Nucleic Acids Res *47*, W270–W275. https://doi.org/10.1093/NAR/GKZ357.

55. Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., and
Huttenhower, C. (2011). Metagenomic biomarker discovery and explanation. Genome
Biol *12*, R60. https://doi.org/10.1186/GB-2011-12-6-R60.

56.   Yoon, S.-H., Ha, S.-M., Kwon, S., Lim, J., Kim, Y., Seo, H., and Chun, J. (2017).
1169   Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences
1170   and whole-genome assemblies. Int J Syst Evol Microbiol *67*, 1613–1617.
1171   https://doi.org/10.1099/ijsem.0.001755.

1172   57.   Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for
1173   Illumina   sequence   data.   Bioinformatics   *30*,   2114–2120.
1174   https://doi.org/10.1093/BIOINFORMATICS/BTU170.

1175   58.   Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2.
1176   Nature Methods 2012 9:4 *9*, 357–359. https://doi.org/10.1038/nmeth.1923.

1177   59.   Smith, B.J., Zhao, C., Dubinkina, V., Jin, X., Moltzau-Anderson, J., Pollard, K.S., Biohub,
1178   C.Z., and Francisco, S. (2024). Accurate estimation of intraspecific microbial gene
1179   content variation in metagenomic data with MIDAS v3 and StrainPGC. bioRxiv,
1180   2024.04.10.588779. https://doi.org/10.1101/2024.04.10.588779.

1181   60.   Shi, Z.J., Dimitrov, B., Zhao, C., Nayfach, S., and Pollard, K.S. (2021). Fast and accurate
1182   metagenotyping of the human gut microbiome with GT-Pro. Nature Biotechnology 2021
1183   40:4 *40*, 507–516. https://doi.org/10.1038/s41587-021-01102-3.

1184   61.   Almeida, A., Nayfach, S., Boland, M., Strozzi, F., Beracochea, M., Shi, Z.J., Pollard,
1185   K.S., Sakharova, E., Parks, D.H., Hugenholtz, P., et al. (2020). A unified catalog of
1186   204,938 reference genomes from the human gut microbiome. Nature Biotechnology
1187   2020 39:1 *39*, 105–114. https://doi.org/10.1038/s41587-020-0603-3.

1188   62.   Zhao, C., Dimitrov, B., Goldman, M., Nayfach, S., and Pollard, K.S. (2023). MIDAS2:
1189   Metagenomic   Intra-species   Diversity   Analysis   System.   Bioinformatics   *39*.
1190   https://doi.org/10.1093/BIOINFORMATICS/BTAC713.

1191   63.   Deehan, E.C., Zhang, Z., Riva, A., Armet, A.M., Perez-Muñoz, M.E., Nguyen, N.K.,
1192   Krysa, J.A., Seethaler, B., Zhao, Y.-Y., Cole, J., et al. (2022). Elucidating the role of the
1193   gut microbiota in the physiological effects of dietary fiber. Microbiome *10*, 77.
1194   https://doi.org/10.1186/s40168-022-01248-5.

1195   64.   Riva, A., Rasoulimehrabani, H., Cruz-Rubio, J.M., Schnorr, S.L., von Baeckmann, C.,
1196   Inan, D., Nikolov, G., Herbold, C.W., Hausmann, B., Pjevac, P., et al. (2023).
1197   Identification of inulin-responsive bacteria in the gut microbiota via multi-modal activity-
1198   based   sorting.   Nature   Communications   2023   14:1   *14*,   1–15.
1199   https://doi.org/10.1038/s41467-023-43448-z.

1200   65.   Hatzenpichler, R., Scheller, S., Tavormina, P.L., Babin, B.M., Tirrell, D.A., and Orphan,
1201   V.J. (2014). In situ visualization of newly synthesized proteins in
1202   environmental microbes using amino acid tagging and click chemistry. Environ Microbiol
1203   *16*, 2568–2590. https://doi.org/10.1111/1462-2920.12436.

1204   66.   Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
1205   Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source
1206   platform for biological-image analysis. Nature Methods 2012 9:7 *9*, 676–682.
1207   https://doi.org/10.1038/nmeth.2019.

1208   67.   Daims, H., Lücker, S., and Wagner, M. (2006). daime, a novel image analysis program
1209   for microbial ecology and biofilm research. Environ Microbiol *8*, 200–213.
1210   https://doi.org/10.1111/J.1462-2920.2005.00880.X.